Trial Profile
Phase I study of methylphenidate XR-ODT formulation in healthy adults studying pharmacokinetics with and without food.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jun 2015
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Pharmacokinetics
- 29 Jun 2015 New trial record
- 24 Jun 2015 Results published in a Neos Therapeutics Media Release. Results were also presented at the 2015 annual meeting of American Society of Clinical Psychopharmacology (ASCP).